5:25 PM
 | 
Jun 10, 2014
 |  BC Extra  |  Company News

Allergan rejects revised Valeant bid

Allergan Inc. (NYSE:AGN) said its board unanimously rejected a revised unsolicited offer to be acquired by Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) in a cash and stock deal that values Allergan at up to $62.2 billion. Allergan said the proposal "substantially undervalues" the...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >